915 related articles for article (PubMed ID: 23806056)
21. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
22. Correlation Between the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated with Hashimoto's Thyroiditis, BRAF V600E Gene Mutation, and RET Gene Rearrangement.
Xie M; Xu ZX; Dai M; Zhu YY
J Coll Physicians Surg Pak; 2024 Apr; 34(4):445-450. PubMed ID: 38576288
[TBL] [Abstract][Full Text] [Related]
23. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
Soares P; Trovisco V; Rocha AS; Lima J; Castro P; Preto A; Máximo V; Botelho T; Seruca R; Sobrinho-Simões M
Oncogene; 2003 Jul; 22(29):4578-80. PubMed ID: 12881714
[TBL] [Abstract][Full Text] [Related]
24. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings.
Sapio MR; Posca D; Raggioli A; Guerra A; Marotta V; Deandrea M; Motta M; Limone PP; Troncone G; Caleo A; Rossi G; Fenzi G; Vitale M
Clin Endocrinol (Oxf); 2007 May; 66(5):678-83. PubMed ID: 17381488
[TBL] [Abstract][Full Text] [Related]
25. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
[TBL] [Abstract][Full Text] [Related]
26. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
[TBL] [Abstract][Full Text] [Related]
27. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
[TBL] [Abstract][Full Text] [Related]
28. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
29. Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries.
Vuong HG; Kondo T; Oishi N; Nakazawa T; Mochizuki K; Inoue T; Tahara I; Kasai K; Hirokawa M; Tran TM; Katoh R
Cancer Med; 2016 Aug; 5(8):1883-9. PubMed ID: 27264674
[TBL] [Abstract][Full Text] [Related]
30. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas.
Lima J; Trovisco V; Soares P; Máximo V; Magalhães J; Salvatore G; Santoro M; Bogdanova T; Tronko M; Abrosimov A; Jeremiah S; Thomas G; Williams D; Sobrinho-Simões M
J Clin Endocrinol Metab; 2004 Sep; 89(9):4267-71. PubMed ID: 15356020
[TBL] [Abstract][Full Text] [Related]
31. The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma.
Guerra A; Sapio MR; Marotta V; Campanile E; Rossi S; Forno I; Fugazzola L; Budillon A; Moccia T; Fenzi G; Vitale M
J Clin Endocrinol Metab; 2012 Feb; 97(2):517-24. PubMed ID: 22170714
[TBL] [Abstract][Full Text] [Related]
32. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
Gandolfi G; Sancisi V; Torricelli F; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A
J Clin Endocrinol Metab; 2013 May; 98(5):E934-42. PubMed ID: 23533235
[TBL] [Abstract][Full Text] [Related]
33. Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma.
Domingues R; Mendonça E; Sobrinho L; Bugalho MJ
Cytopathology; 2005 Feb; 16(1):27-31. PubMed ID: 15859312
[TBL] [Abstract][Full Text] [Related]
34. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
[TBL] [Abstract][Full Text] [Related]
35. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
36.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
37. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma].
Zhu XL; Zhou XY; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):270-4. PubMed ID: 16181547
[TBL] [Abstract][Full Text] [Related]
38. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
39. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
40. RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics.
Leeman-Neill RJ; Brenner AV; Little MP; Bogdanova TI; Hatch M; Zurnadzy LY; Mabuchi K; Tronko MD; Nikiforov YE
Cancer; 2013 May; 119(10):1792-9. PubMed ID: 23436219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]